IP Library Granted Patent US 8,268,962
Granted Patent B2
US 8,268,962 · App. 12/685,369 · Granted Sep 18, 2012

Molecules for targeting compounds to various selected organs or tissues

Assignee: Prosensa Technologies B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,962
App. No.
12/685,369
Granted
Sep 18, 2012
Kind
B2
Abstract

The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detectable agent. In addition the invention provides methods to diagnose or treat a pathology of the muscle or heart, by administrating to a subject having or suspected of having a pathology a molecule or conjugate that homes to, binds to and is taken up by the muscle cells or heart cells.

Claims (10)

1. A conjugate of a peptide or peptidomimetic comprising the sequence or consisting of the sequence LGAQSNF (SEQ ID NO: 100) linked to a moiety selected from a biologically active moiety and a diagnostic moiety.

2. The conjugate according to claim 1 , wherein the biologically active moiety is selected from the group consisting of DNA, RNA or analogues thereof.

3. The conjugate according to claim 1 wherein the conjugate is a fusion protein comprising a peptide of SEQ ID NO: 100 and a therapeutically active protein and/or a diagnostic protein.

4. The conjugate according to claim 3 which further comprises a nuclear localisation signal.

5. A pharmaceutical composition comprising a conjugate according to claim 1 , in combination with a pharmaceutically acceptable carrier.

6. The pharmaceutical composition according to claim 5 wherein the pharmaceutical composition is for the treatment of a muscle-cell associated disorder including cardiac disorders.

7. The pharmaceutical composition according to claim 6 wherein the pharmaceutical composition is for the treatment of a myopathy, muscular dystrophy or muscle wasting disease.

8. The pharmaceutical composition according to claim 5 wherein the pharmaceutical composition is for the treatment of diabetes mellitus type II or obesity.

9. A molecule comprising a peptide or peptidomimetic comprising the sequence or consisting of the sequence LGAQSNF (SEQ ID NO: 100) and a linking portion which is not a peptide for linking the molecule to a biologically active moiety or a diagnostic moiety.

10. The conjugate according to claim 2 , wherein the biologically active molecule is a DNA or RNA analogue selected from the group consisting of 2′-O-alkyl, 2′-O -mehoxyethyl- , 2′-O-methyl, 2′-O-alkenyl (allyl), 2′-O-alkynyl nucleotides, locked nucleic acids (LNAs), peptide nucleic acids (PNAs), ethylene bridged nucleic acids (ENAs), phosphorothioate modified nucleotides, morpholino based nucleotides and combinations thereof.

Assignments (3)
CHANGE OF NAME Recorded Sep 30, 2015
From: PROSENSA TECHNOLOGIES B.V.
To: BIOMARIN TECHNOLOGIES B.V.
Reel/Frame 036732/0042 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Feb 5, 2015
From: PROSENSA TECHNOLOGIES B.V.
To: PROSENSA TECHNOLOGIES B.V.
Reel/Frame 034916/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2010
From: HEEMSKERK, JOHANNES ANTONIUS; VAN DEUTEKOM, JUDITH CHRISTINA THEODORA; VAN KUIK-ROMEIJN, PETRA; PLATENBURG, GERARD JOHANNES
To: PROSENSA TECHNOLOGIES B.V.
Reel/Frame 024134/0506 →
Priority Claims (2)
EP 07112323 · Jul 12, 2007 · regional
WO PCT/NL2008/050475 · Jul 14, 2008 · international
Continuity (1)
Related Publication 20100184948A1 · Jul 22, 2010